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ORIGINAL ARTICLEWeight-based antibiotic dosing in a real-world European study of
complicated skin and soft-tissue infections due to methicillin-resistant
Staphylococcus aureusW. Lawson1, D. Nathwani2, C. Eckmann3, S. Corman4, J. Stephens4, C. Solem4, C. Macahilig5, J. Li6, N. Baillon-Plot7,
C. Charbonneau7 and S. Haider8
1) Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, 2) Ninewells Hospital and Medical School, Dundee, UK, 3) Klinikum Peine, Academic
Hospital of Medical University Hannover, Peine, Germany, 4) Pharmerit International, Bethesda, MD, 5) Medical Data Analytics, Parsippany, NJ, 6) Pﬁzer Inc., San
Diego, CA, USA, 7) Pﬁzer Inc., Paris, France and 8) Pﬁzer Inc., Groton, CT, USAAbstractWe aimed to characterize real-world dosing of weight-based intravenous (IV) antibiotic therapy in patients hospitalized for methicillin-
resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infections (cSSTIs). This was a subgroup analysis of a retrospective
chart review that captured data from 12 European countries. The study included patients 18 years old, hospitalized with an MRSA
cSSTI between 1 July 2010 and 30 June 2011 and discharged alive by 31 July 2011. Patients treated with IV vancomycin, teicoplanin or
daptomycin at any stage during hospitalization were included in this analysis. Analyses were conducted at the regimen level (dosing in mg/
kg or in mg, frequency, and total daily dose (TDD)), with potentially multiple regimens per patient, and the patient level, categorizing
patients into low, standard (labelled) and high dosing groups according to their initial MRSA-targeted regimen. Among the 1502 patients
in the parent study, 998 patients contributed a total of 1050 daptomycin, teicoplanin or vancomycin regimens. Across all regimens, the
mean initial TDDs were 6.3 ± 1.9 mg/kg for daptomycin, 10.5 ± 4.9 mg/kg for teicoplanin and 28.5 ± 11.5 mg/kg for vancomycin. A total
of 789 patients received ﬁrst-line therapy with one of the above antibiotics. The majority of patients receiving ﬁrst-line teicoplanin and
daptomycin (96% and 80%, respectively) received higher than labelled cSSTI doses, whereas vancomycin doses were lower than labelled
doses in >40% of patients. These real-world data reveal signiﬁcant deviation from labelled antibiotic dosing in 12 European countries and
the potential for suboptimal outcomes in patients with MRSA cSSTIs.
© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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p://dx.doi.org/10.1016/j.cmi.2015.05.030IntroductionPatients with complicated skin and soft tissue infections (cSSTIs)
caused by methicillin-resistant Staphylococcus aureus (MRSA)
commonly receive intravenous (IV) therapy with antibiotics
such as vancomycin, teicoplanin or daptomycin [1]. Recom-
mended dosing of these agents is available from a variety of
sources, sometimes with conﬂicting recommendations. For
example, recommended doses for IV vancomycin differiety of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
CMI Lawson et al. Weight-based antibiotic dosing in MRSA SSTIs S41between the product labelling or licensed dosing (2000 mg/day)
[2] and published evidence-based guidelines (30 mg/kg/day)
[1,3], with weight-based dosing recommended primarily
because of the potential for under-dosing in obese patients with
increased volumes of distribution [4,5]. Even when dosing
recommendations are consistent, as is the case for daptomycin,
doses used in practice frequently differ from those recom-
mended [6].
In order to optimize MRSA antibiotic therapies in patients
with MRSA cSSTIs, it is important to accurately characterize the
current use of parenteral antibiotic therapy. We therefore
performed a subgroup analysis of data obtained from a pan-
European retrospective observational medical chart review
study to describe real-world, weight-based dosing patterns for
daptomycin, teicoplanin and vancomycin therapy in patients
hospitalized across 12 European countries for the treatment of
MRSA cSSTIs. Additionally, we identiﬁed antibiotic dosing pat-
terns according to patient demographics and clinical charac-
teristics, and explored dosing patterns by country.MethodsTABLE 1. Daptomycin, teicoplanin and vancomycin labelled
doses at study initiation for the treatment of methicillin-
resistant Staphylococcus aureus complicated skin and soft-
tissue infections (cSSTIs) and corresponding dose categories
Drug
Recommended dose(s)
for cSSTIs
Dose categories
(mg/kg/day)
Daptomycin 4 mg/kg every 24 hours [11] − Low dose <4.0
− Standard dose 4.0
− High dose >4.0
Teicoplanin 400 mg loading dose (6 mg/kg)
followed by 200 mg
(3 mg/kg) every 24 h [10]
− Low dose <3.0
− Standard dose
3.0–3.3a,b
− High dose 3.4
Vancomycin 2000 mg/day, divided as
1000 mg every 12 h or
500 mg every 6 h [2]
− Low dose <25.0
− Standard dose
25.0–35.0a
− High dose >35.030 mg/kg/day in two
divided doses [1,3]
aA range of doses was used to deﬁne standard dosing to account for dose rounding.
bUpper end of dosing range assumes a 6 mg/kg loading dose, followed by 3 mg/kg/
day for a total of 10 days.This subgroup analysis evaluated data obtained from a retro-
spective, observational medical chart review study that
captured patient information via 342 physicians in 12 European
countries [7–9]. Data were obtained from hospital records of
patients aged 18 years of age or older hospitalized with a
documented MRSA cSSTI between 1 July 2010 and 30 June
2011 and discharged alive by 31 July 2011. Individuals were
excluded if they had suspected or proven diabetic foot infec-
tion, osteomyelitis, infective endocarditis, meningitis, joint
infection, necrotizing fasciitis, gangrene, prosthetic joint infec-
tion or prosthetic implant/device infection, signiﬁcant
concomitant infection at other sites (e.g. bacteraemia, pneu-
monia) or if they had been treated for the same MRSA cSSTI
within 3 months of hospitalization. Only patients who used IV
vancomycin, teicoplanin or daptomycin at any stage during
hospitalization were included within this sub-analysis.
Study investigators randomly selected patients from all the
patients in their practice who met the enrolment criteria.
Speciﬁcally, investigators were instructed to select patients
based on randomly assigned birth month and hospitalization
month. Data collected included demographic and clinical
characteristics, MRSA-targeted IV and oral antibiotic use, and
hospital resource use (e.g. length of stay, surgical and diagnostic
procedures). The initial MRSA-targeted antibiotic regimen and
any subsequent regimens used within the same stay were
documented for each patient. Starting and ending doses were
collected for each regimen to identify any dose changes that© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behal
This is an open access artioccurred during the course of therapy. Doses that were
considered clinically implausible and/or to have been incor-
rectly transcribed (teicoplanin starting doses 2 mg/kg/day and
any vancomycin dose 5 mg/kg/day) were excluded from the
analysis. Patients were classiﬁed according to the initial IV
antibiotic used, without regard for drug or dose changes during
the course of therapy.
The primary study outcome was the percentage of patients
receiving dosing regimens categorized as low, standard, or high
(Table 1) based on the total daily dose (TDD) in mg/kg and the
labelled or guideline-recommended daily dose at the time the
study was conducted [1–3,10,11]. For this analysis, patients
were categorized according to the ﬁrst antibiotic drug pre-
scribed and the dose at the start of therapy, regardless of any
subsequent antibiotic switching or dose changes. TDD was
calculated for each regimen, both in mg and mg/kg, when data
permitted; TDD in mg could not be calculated for patients
prescribed a weight-based regimen if their weight was not
recorded. The proportion of patients in each dosing category
was calculated for each drug, overall and by country. Descrip-
tive statistics were used to summarize patient demographic and
clinical characteristics by dosing category. Characteristics that
appeared to be distributed differently among groups were
further analysed using chi-squared and t-tests to identify dosing
trends.
Secondary outcomes were analysed at the regimen level,
with patients being able to contribute multiple regimens if there
were drug or dose changes during the course of treatment.
These outcomes included the TDD in mg for each antibiotic at
the start and end of therapy, and the distribution of actualf of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, S40–S46
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
S42 Clinical Microbiology and Infection, Volume 21 Number S2, September 2015 CMIprescribed regimens (drug, dose and frequency). Other out-
comes included the proportion of antibiotic dosing regimens
written in mg/kg (weight-based dosing) or mg (ﬂat dosing), and
the distribution of regimens by dosing frequency (one to four
daily doses).ResultsA total of 1502 patients were included in the parent study. Of
these, 977 patients (65%) received ﬁrst-line therapy with one of
the antibiotics of interest; 836 of these patients had sufﬁcient
data documented to classify the dosing regimen administered.
One patient receiving teicoplanin and 46 patients receiving
vancomycin were excluded because of clinically implausible
doses, with a total of 789 patients remaining for analysis (Fig. 1).
Of note, 43.4% of the patients receiving ﬁrst-line vancomycin
were dosed at <25 mg/kg/day, and ﬁrst-line teicoplanin regi-
mens were almost all 3.4 mg/kg/day (96%). First-line dapto-
mycin doses exceeded 4 mg/kg/day in the majority of patients
(80%), and no patients received <4 mg/kg/day. The distribution
of category of dosing at start of initial therapy, stratiﬁed by
country, is shown in Table 2. Countries where >50% of van-
comycin starting doses were <25 mg/kg/day were Austria,
Czech Republic, Germany, Greece, Portugal and Spain. For
daptomycin all starting doses were >4 mg/kg/day in Spain, UKFIG. 1. Analysis of methicillin-resistant Staphylococcus aureus (MRSA) complic
*Deﬁned as any vancomycin dose 5 mg/kg/day; **deﬁned as a teicoplanin s
© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Soc
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceand Slovakia; however, this reﬂects only one patient in Slovakia.
Daptomycin dosing was in accordance with the labelled dose
for MRSA cSSTI (4 mg/kg/day) >50% of the time in Austria; in all
other countries, dosing was predominantly >4 mg/kg. No pa-
tients received daptomycin as the initial therapy for MRSA
cSSTIs in Czech Republic, Ireland, Portugal or Poland.
Demographic and clinical characteristics of study patients by
drug and dosing category are shown in Table 3. Among patients
for whom height and weight data were recorded, obesity was
over twice as common among patients receiving vancomycin
doses of <25 mg/kg/day (69.9%) than in patients receiving
higher doses (33.0% and 27.3% in the standard and high-dose
groups, respectively; p < 0.001). The prevalence of moderate
to severe renal dysfunction (as deﬁned and documented in the
medical record) was higher in patients receiving a vancomycin
daily dose of <25 mg/kg (18.8%) than in those receiving a daily
dose of 25 mg/kg (8.8%; p < 0.001). Further exploration of
vancomycin dosing revealed that the mean TDD at the start of
therapy was lower in patients with moderate to severe renal
insufﬁciency (1556 mg) compared with those without renal
insufﬁciency (2017 mg; p < 0.001). Because of the small
numbers of patients in several of the teicoplanin and dapto-
mycin dosing categories, no conclusions regarding dosing
trends can be drawn.
For the antibiotic dosing regimen-level analyses, a total of
945 patients (63%) contributed a total of 997 antibioticated skin and soft-tissue infection (cSSTI) antibiotic treatment patterns.
tarting dose 2 mg/kg/day; IV, intravenous.
iety of Clinical Microbiology and Infectious Diseases, CMI, 21, S40–S46
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TABLE 2. Vancomycin and daptomycin total daily dose (in mg/kg/day) at start of therapy by country (initial regimen)a
CMI Lawson et al. Weight-based antibiotic dosing in MRSA SSTIs S43regimens that included daptomycin (n = 110), teicoplanin
(n = 178) or vancomycin (n = 709). There was signiﬁcant
variability in the dosing regimens prescribed for all three drugs.
The most frequently prescribed regimen for each drug was
administered to approximately 25% of patients (Table 4). The
mean initial TDDs were 6.3 ± 1.9 mg/kg for daptomycin,
10.5 ± 4.9 mg/kg for teicoplanin and 28.5 ± 11.5 mg/kg for
vancomycin. Mean and median TDD for daptomycin- and
vancomycin-treated patients were similar at the start and end of
therapy, whereas the mean and median TDD for teicoplanin
were higher at the start compared to the end of therapy,
reﬂecting loading dose administration (Table 5).© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behal
This is an open access artiA ﬂat or mg dosing regimen was prescribed for the majority of
teicoplanin (89%) and vancomycin (76%) regimens, whereas
weight-based dosing was used most frequently for daptomycin
(59%). At the start of therapy, vancomycin was most often dosed
twice daily (56%), followed by once daily (22%), four times daily
(15%) and three times daily (7%). Teicoplanin starting doses
were equally divided between twice daily (50%) and once daily
(48%), with a few regimens dosed three times daily (2%). Dap-
tomycin was dosed once daily almost universally (98%), with the
remaining regimens dosed three times daily (2%).
A post hoc analysis was conducted to describe the dosing
of teicoplanin using the updated labelled dose approved inf of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, S40–S46
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 3. Patient characteristics by initial methicillin-resistant Staphylococcus aureus-targeted regimen
Total daily dose, mg/kg
Vancomycin (n [ 590) Teicoplanin (n [ 122) Daptomycin (n [ 87)
<25 25–35 >35 <3.0 3.0–3.3 ‡3.4 4.0 >4.0
Patients, n (%) 256 (43.4) 250 (42.4) 84 (14.2) 2 (1.8) 2 (1.8) 11 (96.4) 15 (17.2) 62 (71.3)
Male, % 60.6 65.6 53.6 0 50.0 61.0 66.7 62.9
Age, yearsa 62.7 ± 14.9 59.0 ± 16.1 52.3 ± 16.7 64.0 ± 8.5 49.5 ± 19.1 62.3 ± 16.4 60.6 ± 11.9 55.0 ± 17.3
Weight, kg (n)a,b 82.1 ± 13.4 (245) 73.4 ± 11.7 (243) 67.0 ± 13.4 (80) 74.5 ± 4.9 (2) 69.0 ± 12.7 (2) 76.3 ± 16.9 (118) 75.7 ± 9.7 (13) 76.8 ± 13.6 (55)
Obese, % (n)b,c 69.9% (226) 33.0% (212) 27.3% (66) 50.0% (2) 100% (1) 44.9% (98) 38.5% (13) 48.8% (43)
Comorbidities, %
Diabetes 37.5 27.6 29.8 50.0 0 31.4 40.0 11.3
Peripheral vascular disease 31.6 17.6 21.4 100 0 17.0 33.3 22.6
Chronic pulmonary disease 20.7 23.2 8.3 33.3 100 22.9 20.0 19.4
Coronary artery disease 27.3 14.4 8.3 0 50 12.7 13.3 19.4
Congestive heart failure 28.9 12.0 6.0 0 0 12.7 26.7 14.5
Moderate to severe renal
disease
18.8 8.8 6.0 100 0 5.1 0 9.7
Cerebrovascular disease 12.9 7.6 10.7 0 0 11.9 0 6.5
Mild liver disease 13.7 9.2 8.3 0 0 10.2 0 12.9
Peptic ulcer disease 9.0 8.8 8.3 0 50 7.6 6.7 16.1
Dementia 8.2 5.2 3.6 0 0 6.8 6.7 3.2
Complicated skin and skin structure infection type, %
Deep/extensive cellulitis 25.8 23.6 25.0 0 0 22.0 20.0 35.5
Infected ulcer 26.2 22.4 15.5 100 0 28.8 26.7 14.5
Major abscess 15.6 22.4 21.4 0 0 18.6 13.3 19.4
Post-traumatic wound
infection
16.0 15.6 14.3 0 100 12.7 13.3 12.9
Surgical site infection 10.6 11.6 17.9 0 0 12.7 20.0 9.7
Infected burn 6.9 3.2 6.0 0 0 3.4 6.7 6.5
Other 0 1.2 0 0 0 1.7 0 1.6
Sepsis, % 24.6 19.6 19.1 0 0 13.6 26.7 16.1
aMean ± SD.
bNumber of patients with data available.
cObese deﬁned as >120% of ideal body weight; could not be determined for patients with weight and/or height data not recorded.
S44 Clinical Microbiology and Infection, Volume 21 Number S2, September 2015 CMI2013 [12]. A daily dose of <6 mg/kg was classiﬁed as low
dose, 6–6.6 mg/kg as standard dose, and >6.6 mg/kg as high
dose. This analysis found that the majority of teicoplanin
starting doses (70%) were still in the high-dose category.
Approximately 5% of teicoplanin doses were classiﬁed
as standard dose and 25% of doses were classiﬁed as low
dose.TABLE 4. Daptomycin, teicoplanin and vancomycin regimens
prescribed for >5% of patients (any stage or regimen)
Drug Regimen n (%)
Daptomycin (n = 110) 6 mg/kg daily 27 (24.5)
500 mg daily 23 (20.9)
4 mg/kg daily 19 (17.3)
8 mg/kg daily 12 (10.9)
350 mg daily 8 (7.3)
700 mg daily 7 (6.4)
Other 14 (12.7)
Teicoplanin (n = 178) 400 mg daily 42 (23.6)
400 mg twice daily 42 (23.6)
800 mg daily 21 (11.8)
200 mg twice daily 15 (8.4)
600 mg twice daily 14 (7.9)
Other 44 (24.7)
Vancomycin (n = 709) 1000 mg twice daily 203 (28.6)
500 mg four times daily 90 (12.7)
500 mg twice daily 72 (10.1)
1000 mg daily 55 (7.8)
15 mg/kg twice daily 48 (6.8)
30 mg/kg daily 46 (6.5)
Other 195 (27.5)
© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Soc
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceDiscussionResults from this analysis of real-world IV antibiotic use for the
treatment of hospitalized patients with MRSA cSSTIs show
considerable variation in antibiotic dosing practices among the
12 European countries outlined. This variability may result from
country-speciﬁc practice patterns, and possible differences in
the disciplines involved in antibiotic prescribing (e.g. infectious
disease specialists, antibiotic stewardship teams, pharmacists)
across countries. Doses were prescribed in mg for the majority
of teicoplanin or vancomycin regimens, whereas weight-based
dosing (i.e. mg/kg) was prescribed for the majority of dapto-
mycin regimens. The initial dosing frequency prescribed most
commonly for vancomycin regimens was twice daily and for
daptomycin regimens was once daily. Teicoplanin regimens
were almost equally split between once and twice daily. In
general, there was signiﬁcant variability in the dosing regimens
prescribed for all three drugs.
The most common vancomycin dosage regimen in this study
was 1000 mg IV twice daily. Analysis of initial MRSA-targeted
regimens by weight showed that over 40% of the patients
receiving vancomycin for an MRSA cSSTI received a daily dose
<25 mg/kg. This dose is less than the recommended daily dose
of 30–60 mg/kg for patients with normal renal function [3,13].iety of Clinical Microbiology and Infectious Diseases, CMI, 21, S40–S46
nses/by-nc-nd/4.0/)
TABLE 5. Daptomycin, teicoplanin and vancomycin mean and
median initial and ﬁnal total daily dose (any stage of regimen)
Vancomycin Teicoplanin Daptomycin
Patients, n/Na 683/709 177/178 96/110
Mean daily dose ± SD, mg
Start of therapy 1915.4 ± 788.0 707.2 ± 339.2 486.9 ± 147.2
End of therapy 1848.2 ± 798.8 514.1 ± 299.5 477.4 ± 144.2
Median daily dose (range), mg
Start of therapy 2000 (500–7080) 800 (180–1872) 500 (240–1080)
End of therapy 2000 (500–7080) 400 (100–2000) 500 (240–1080)
an, number of patients for whom the total daily dose could be calculated (patient
weight available); N, total number of patients receiving drug.
CMI Lawson et al. Weight-based antibiotic dosing in MRSA SSTIs S45Administration of low vancomycin doses may not only decrease
vancomycin effectiveness but also increase the development of
vancomycin intermediate susceptible and/or vancomycin-
resistant S. aureus strains [13]. However, as this study did not
collect vancomycin serum levels or institution-speciﬁc MICs,
we could not evaluate the potential for development of resis-
tant organisms at the various institutions.
Analysis of patient-level data found an increasing prevalence
of renal dysfunction and obesity with decreasing vancomycin
dose. As expected, analysis of vancomycin dosing based on
patient renal status found that patients with moderate to severe
renal insufﬁciency, compared with those without, received
lower vancomycin daily dose. However, as vancomycin levels
and local reference ranges were not collected, we were unable
to determine whether vancomycin was appropriately dosed
according to renal function. With regard to obesity, current
recommendations are to dose vancomycin based on a patient’s
actual body weight, not ideal body weight [13]. Use of ideal
body weight would result in a lower mg/kg dose for obese
patients and could negatively affect patient outcome. In this
study, we found that almost 70% of patients receiving a van-
comycin daily dose of <25 mg/kg were obese.
Comparison of the average starting and ending teicoplanin
doses suggests the use of a teicoplanin loading dose for some
patients, although we do not have the data needed to conﬁrm
that this is indeed the case. Although the labelled dosing of
teicoplanin at study initiation consisted of a 6-mg/kg loading
dose on day 1 followed by a 3-mg/kg daily maintenance dose
[10], >50% of teicoplanin starting regimens were dosed more
frequently than once daily at treatment initiation. Analysis of the
ending teicoplanin dose suggests use of a higher than recom-
mended teicoplanin maintenance dose (mean daily dose of
510 mg).
These higher teicoplanin doses may reﬂect data supporting
the teicoplanin label change made in late 2013. In October
2013, the teicoplanin label was revised and a new dose for
treating MRSA cSSTIs was included. The new recommended
teicoplanin dose for patients with MRSA cSSTIs is 400 mg
(~6 mg/kg) every 12 h for three doses followed by a daily dose© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behal
This is an open access artiof 6 mg/kg [12]. However, it should be noted that this change
was some time after the patients included within this study
were treated. In addition, a targeted trough concentration of
>15 mg/L by ﬂuorescence polarization immunoassay is rec-
ommended in the product labelling. There is other evidence to
suggest that even higher than recommended teicoplanin doses
are needed to achieve therapeutic drug levels of 20–60 mg/L
[14]; however, because our study did not collect teicoplanin
serum levels, we could not evaluate the adequacy of dosing
according to the recommended range.
The majority of patients (80%) prescribed ﬁrst-line dapto-
mycin in this study received a dose that exceeded the approved
and recommended 4 mg/kg daily dose for the treatment of
MRSA cSSTIs [1,3,11]. In four of the 12 study countries
(Portugal, Slovakia, Spain, UK), high doses were used exclu-
sively. Although it is possible that some of the high doses of
daptomycin can be explained by dose rounding, analysis by
dosing regimen found that the most common daptomycin
regimen used in this study was daptomycin 6 mg/kg/day, the
recommended daily dose for the treatment of bacteraemia [11];
however, patients with bacteraemia were excluded from this
study. These results are consistent with data from the last
analysis of the European registry for the Cubicin® Outcomes
Registry and Experience (EU-CORE), which showed that 43%
of patients treated for cSSTIs received a daptomycin daily dose
of 6 mg/kg or more [6]. Use of higher than approved and
recommended daptomycin doses for the treatment of cSSTIs
has not only economic but also clinical implications. Whereas
patients receiving a dose of 6 mg/kg/day had elevations in cre-
atine phosphokinase more frequently than patients receiving
comparator regimens (6.7% versus 0.9%; p 0.004), doses of
4 mg/kg/day were not signiﬁcantly associated with creatine
phosphokinase elevations (2.1% versus 1.4% for comparator
regimens) [15,16].
Several limitations of the study reﬂect the observational
design of the parent study and the post hoc nature of the
analysis. Data collected on antibiotic dosing were limited to
starting and ending regimens, and so any other dose changes
were not captured. We were unable to make associations be-
tween antibiotic dosing and clinical outcomes because treat-
ment success rates were collected only at discharge, with >99%
of patients exhibiting cure or improvement, regardless of the
antibiotic prescribed.
In conclusion, results from this real-world analysis of
parenteral antibiotic treatment patterns in patients with MRSA
cSSTIs hospitalized in Europe show wide variability in dosing
regimens for patients with MRSA cSSTIs, particularly the
frequent use of higher than labelled doses for teicoplanin and
daptomycin, and the issue of potential under-dosing of vanco-
mycin in obese patients. These data reveal signiﬁcant variationf of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, S40–S46
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
S46 Clinical Microbiology and Infection, Volume 21 Number S2, September 2015 CMIin clinical practice and the potential for suboptimal clinical and
economic outcomes. Clinicians with patients with MRSA cSSTIs
under their care should be cognisant of the recommended
dosing of MRSA-active antibiotics in order to maximize clinical
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